HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae.

Abstract
Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated. The MICs were determined by using a 2-fold agar dilution method. Mathematical models were developed to characterize the pharmacokinetic profile of benapenem in humans and mice. Monte Carlo simulations were employed to determine the cutoff values and the appropriate benapenem dosing regimens for the treatment of infections caused by clinical isolates of Enterobacteriaceae Two 2-compartment models were developed to describe the PK profiles of benapenem in humans and mice. A two-site binding model was applied to fit the protein binding in mouse plasma. Through correlation analysis, the percentage of the time that the free drug concentration remains above the MIC (%fT>MIC) was determined to be the indicator of efficacy. Results from the simulation showed that the probability of target attainment (PTA) against the tested isolates was over 90% with the dosing regimens studied. The PK/PD cutoff value of benapenem was 1 mg/liter at a %fT>MIC of 60% when given at a dose of 1,000 mg/day by i.v. drip for 0.5 h. The established model provides a better understanding of the pharmacological properties of benapenem for the treatment of Enterobacteriaceae infections. The proposed PK/PD cutoff value suggests that benapenem is a promising antibacterial against the Enterobacteriaceae The cutoff value of 1 mg/liter may be a useful guide for the clinical use of benapenem and for surveillance for benapenem resistance.
AuthorsXi-Wei Ji, Feng Xue, Zi-Sheng Kang, Wei Zhong, Isabelle Hui-San Kuan, Xi-Ping Yang, Xiao Zhu, Yun Li, Yuan Lv
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 64 Issue 3 (02 21 2020) ISSN: 1098-6596 [Electronic] United States
PMID31844001 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Ji et al.
Chemical References
  • Anti-Bacterial Agents
  • Carbapenems
  • benapenem
  • Ertapenem
Topics
  • Adult
  • Animals
  • Anti-Bacterial Agents (blood, pharmacokinetics, pharmacology)
  • Area Under Curve
  • Carbapenems (blood, pharmacokinetics, pharmacology)
  • Drug Development
  • Enterobacter cloacae (drug effects, growth & development)
  • Enterobacteriaceae Infections (blood, drug therapy, microbiology, pathology)
  • Ertapenem (blood, pharmacokinetics, pharmacology)
  • Escherichia coli (drug effects, growth & development)
  • Female
  • Humans
  • Klebsiella pneumoniae (drug effects, growth & development)
  • Male
  • Mice
  • Mice, Inbred ICR
  • Microbial Sensitivity Tests
  • Models, Statistical
  • Monte Carlo Method

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: